Researchers presented prospective evidence at the International Symposium on Pediatric Neuro-Oncology supporting retreatment with the MEK inhibitor selumetinib in children with recurrent low-grade glioma. The findings suggest that reintroducing the drug after disease progression—following an initial period of response or stability and subsequent treatment discontinuation—can effectively control tumor growth in this patient population.

The study, which focused on arm 29C of the PBTC-029 trial led by the Pediatric Brain Tumor Consortium, enrolled 35 children who had previously participated in phase I or phase II trials of selumetinib and later experienced disease progression after stopping the drug. Investigators specifically examined whether retreatment could serve as a viable therapeutic strategy for patients who initially benefited from the medication but saw their tumors return after treatment cessation. Success was predefined as either a clinical response or maintenance of stable disease for at least 12 months—or 12 cycles—of retreatment therapy.

The trial met all predetermined statistical parameters for success, with over 80% of participants achieving stable disease for 12 months or longer. A small fraction of patients exhibited measurable tumor responses to the reintroduction of the drug, further reinforcing its biological activity upon retreatment. Jason Fangusaro, a physician at Emory University School of Medicine in Atlanta, emphasized the clinical implications of these results. "Retreatment using selumetinib if you recur after stopping the drug -- not during using the drug -- is an effective strategy moving forward," he said.

Fangusaro noted that historical practice often involved switching to an alternative therapy upon recurrence after treatment discontinuation. "Historically people would often change to a different drug if they recurred after stopping," he said. However, the new data challenge that approach by demonstrating that returning to selumetinib can yield durable disease control. He added, "This was the first time we've ever shown that prospectively in a large number of patients, that retreatment is an effective strategy."

Selumetinib, a MEK inhibitor that has been studied for years in pediatric low-grade glioma, was originally evaluated in the broader PBTC-029 trial, which assessed its efficacy in children with recurrent forms of the disease. The current findings specifically isolate the retreatment cohort, providing targeted evidence for a subset of patients whose treatment course includes a planned or necessary break followed by relapse. Fangusaro concluded that the results carry clear clinical guidance: "These data prospectively show more definitively that that is an appropriate strategy and should be strongly considered in this patient population."

Low-grade gliomas are the most common type of brain tumor in children, and while often slow-growing, they can cause neurological complications and frequently require long-term management. Treatment decisions become especially complex when tumors recur after an initial response, as clinicians must weigh the risks of prolonged drug exposure against the uncertainty of switching therapies. This study provides the first prospective, statistically validated evidence that retreatment with the same MEK inhibitor can maintain disease control in such cases, potentially sparing patients from less effective or more toxic alternatives.

The findings may influence clinical guidelines for managing pediatric low-grade glioma, particularly for patients who previously tolerated and benefited from selumetinib. With over 80% of retreatment patients maintaining stable disease for at least a year, the approach offers a predictable and evidence-based option in a field where therapeutic decisions have often relied on retrospective data or clinical intuition.